Michael D Woodrow,
Stuart P Ballantine,
Michael D Barker,
Beth J Clarke,
John Dawson,
Tony W Dean,
Christopher J Delves,
Brian Evans, Sharon L Gough,
Steven B Guntrip, [......],
Duncan S Holmes,
Michael Kranz,
Mika K Lindvaal,
Fiona S Lucas,
Margarete Neu,
Lisa E Ranshaw,
Yemisi E Solanke,
Don O Somers,
Peter Ward,
Joanne O Wiseman
[show abstract]
[hide abstract]
ABSTRACT: Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B inhibitor which also inhibits LPS induced production of TNF-alpha from isolated human peripheral blood mononuclear cells with a pIC(50) of 11.1. GSK256066 also has a suitable profile for inhaled dosing.
Bioorganic & medicinal chemistry letters 05/2009; 19(17):5261-5. · 2.65 Impact Factor